Frontiers in Medicine
Cure8 research brief
Why This Matters
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and ustekinumab may inform expectations about staying on newer agents.
Who Should Pay Attention
Pediatric and adult IBD patients and families, clinicians managing IBD (especially pediatric gastroenterologists), researchers studying real-world drug use and persistence, and patients currently on or considering biologic therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a descriptive analysis of patients newly diagnosed with UC or CD from 2014–2022 using a national healthcare database. The study found Crohn's disease was more common in the pediatric group and that pediatric patients tended to start advanced therapies sooner after diagnosis than adults.
The report notes that only anti–TNF agents are currently approved for pediatric use in the setting described, and it presents adult persistence data at 12 months for vedolizumab and ustekinumab. The study is observational and reports treatment patterns and persistence; it does not test efficacy in a randomized way or provide new safety data.
The findings may help inform clinicians and families about real-world timing of escalation and patterns of use but do not by themselves establish changes to approved indications.
Keep In Mind
This is a national, observational database study (descriptive) using administrative/medical records from South Korea (2014–2022). It reports patterns and persistence but cannot prove causation or comparative effectiveness. The article notes current pediatric approvals are limited to anti–TNF agents in this setting.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Medicine
PublisherFrontiers Media SA
AuthorsHyunJoo Lim, Ju Hwan Kim, Byong Duk Ye +7 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 15, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...